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Abstract 
High rates of interpatient variability in drug metabolism and drug 
response for nearly all medications lead to the hypothesis that 
assessment of an individual patient's genotype with respect to their 
ability to metabolize certain drugs can be a useful tool in predict-
ing a patient's responsiveness to certain medications. Evaluating 
patients using pharmacogenomics as a basis for assessment could 
allow pharmacists to decide which treatment options would be most 
efficacious in a given patient and, thereby, have significant impact 
in the clinical setting. This holds true especially in the case of 
prodrugs, which require in vivo activation to an active or more active 
form. Codeine is a prodrug whose clinical efficacy depends greatly 
on its metabolism to more active forms by both cytochrome P450 
enzymes and uridine diphosphate glucuronyltransferase enzymes 
and is affected by the activity of transporters and the structure of 
its target receptor.4 Evaluation of a patient's metabolic capacity 
concerning these enzymes, as well as any "abnormalities" in trans-
porter activity or receptor structure, could indicate if the patient will 
receive adequate pain relief from a given dose of codeine. 
Introduction 
In recent years, the connection between drug metabolism and genet-
ics has been more thoroughly validated thanks to studies on genetic 
variability and drug effects.1 For nearly all medications, interpatient 
response variability has been found to be the rule rather than the excep-
tion. It is hypothesized that 20-40 percent of differences in patients with 
respect to drug response can be described by variations in a patient's 
phenotype, the observable traits that result from the genotype, which 
can include the patient's ability to metabolize drugs due to the expres-
sion of enzymesY These variations are commonly identified through 
the discovery of single-nucleotide polymorphisms (SNPs), the most 
common genetic variations in human DNA, which occur when one single 
base pair replaces another.3 Through the use of an individual's genetic 
background and by paying particular attention to those genes coding 
for proteins, such as enzymes, transporters and receptors involved in a 
drug's pharmacokinetics and pharmacodynamics, pharmacists and other 
health care providers can more thoroughly predict a patient's response 
to a specific medication. 
A clinically relevant example of this is the metabolism of codeine. 
Codeine is a prodrug that requires 0-demethylation by cytochrome P450 
(GYP) 2D6 and glucuronidation by uridine diphosphate glucuronyltrans-
ferase 287 (UGT287) to form its more active metabolites, morphine and 
codeine-6-glucuronide.4 Codeine efficacy also may be significantly af-
fected by polymorphisms in the transporter as well as the receptor itself. 
Codeine Metabolism 
The CYP2D6 gene is polymorphic, which results in the metabolism of 
morphine being highly variable.2 A complete lack of GYP2D6 activity is 
seen in 6-7 percent of Caucasians. Of the known polymorphisms, alleles 
*3-*8 have been classified as nonfunctional, which prevents the forma-
tion of functional CYP2D6. Alleles *9, *10 and • 41 have been associated 
with reduced function, and *1, *2, *35 and *41 can be duplicated, which 
would result in a significant increase in the expression of functional 
CYP2D6.5 GYP2D6 phenotype is determined by the allelic combina-
tions that an individual patient possesses, as described in Table 1. The 
frequency of variant CYP2D6 alleles varies greatly interethnically. In 
Extensive Metabolizers (EM), approximately 10 percent of the codeine 
dose is converted to morphine.4 In addition to variations in therapeutic 
response, an individual's genetic makeup can be used to determine the 
safety of codeine. For example, when compared to EMs CYP2D6, poor 
metabolizers (PM) experience less respiratory, psychomotor and pupil-
lary effects, though no significant difference was seen in adverse effects, 
such as sedation or dry mouth, between the two phenotypes. 
Glucuronidation by UGT2B7 accounts for nearly 80 percent of the 
metabolism of a given dose, making it the main route of metabolism 
for codeine. As a result of this, the codeine-6-glucuronide metabolite 
is found at a much higher concentration in the body than codeine, as 
demonstrated by the fact that the area under the curve (AUG) values 
of codeine-6-glucuronide are 10-15 times higher than that of codeine. 
Although the gene that codes for UGT2B7 also has been found to be 
polymorphic, less than 20 allelic variants for this gene have been identi-
fied. 5 Unlike the polymorphisms associated with CYP2D6, the functional 
significance of UGT2B7 polymorphisms has not been well-defined with 
in vitro or in vivo studies. Two significant SNPs with respect to opioid 
metabolism are SNP G211 T of the UGT287 enzyme and the SNP 
A-842 G, which is associated with the regulatory region of the gene that 
encodes UGT287.6 The nomenclature of SNP G211 T denotes that 
guanine is replaced by thymine in the DNA sequence, and SNP A-842 
G means that adenine is replaced by guanine. The SNP G211 T causes 
a change in the amino acid sequence of the resulting protein at position 
71, which changes a lipophilic residue, alanine, in the substrate binding 
pocket to a hydrophilic residue, serine. This substitution was studied in 
a comparison of two cancer patients, and this allele was shown to be 
present in the patient with low morphine sensitivity. The SNP A-842 G 
has been associated with increased promoter activity, resulting in higher 
levels of UGT2B7 and, thus, increased rates in morphine metabolism. 
This increased metabolism can be considered another reason why 
patients may fail to experience adequate pain relief from opioids. 
Another factor that may contribute to the resistance of certain drugs 
is P-glycoprotein (P-gp), an efflux transporter, also known as multi-
drug resistant P-glycoprotein (MRP1 ).2 P-gp limits the distribution and 
enhances the elimination of many drugs from the body in an effort to 
protect against a potentially toxic accumulation of the drug.7 Morphine, 
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methadone, loperamide and fentanyl have all been confirmed as P-gp 
substrates as well as many endogenous and synthetic opioid peptides.5 
Polymorphisms that increase or decrease the levels of P-gp in mem-
branes can alter drug effects accordingly.6 Increased expression of P-gp 
would result in decreased blood concentrations of these drugs, while 
decreased expression would cause the opposite effect. Although P-gp 
is highly expressed at many apical epithelium cell membranes, including 
in the intestine, which influences drug absorption, its most significant 
impact is at capillary endothelial cells of the blood-brain barrier and 
blood-cerebrospinal fluid barrier, where it functions to determine CNS 
exposure to various substrates.5 
The mu opioid receptor, coded for by the opioid receptor, mu 1 (OPRM1) 
gene, is the preferred target of many opioid drugs, especially morphine.8 
There have been more than 100 genetic polymorphisms identified in the 
OPRM1 gene. These variations have been noted to produce more than 
20 amino acid sequences and have polymorphic frequencies of more 
than 1 percent. 5 
Morphine: A Case Report 
According to guidelines from the World Health Organization (WHO), one 
of the leading pharmacological treatments for moderate to severe cancer 
pain is oral morphine.6 However, the analgesic response to morphine 
is variable, and both genetic and non-genetic factors contribute to this 
unpredictability. Some of these genetic factors include variations in the 
genes for the drug's target receptor, drug-metabolizing enzymes and 
drug transporters. A published case report describes the treatment of a 
55-year-old woman with lung carcinoma and bone metastases who was 
given morphine for the treatment of severe pain and did not experience 
an adequate analgesic response. Her morphine dose was increased 
from 20 mg/day to 75 mg/day, but her pain still was not relieved. 
After undergoing genetic testing for several polymorphisms, this patient 
was classified as a poor responder to morphine due to the detection of 
several SNPs.6 One of the SNPs identified was a genetic variation in the 
mu-opioid receptor (MOR-1 ). The patient was found to be heterozygous 
for the MOR-1 polymorphism A 118 G, a genotype that typically results 
in patients needing an 18 percent higher dose of morphine compared 
to patients with the wildtype genotype. In addition, the patient had a 
genetic variation involving the UGT2B7, which altered the production 
of normal metabolites of morphine, one of which is active at opioid 
receptors and one that is inactive. This patient was homozygous for the 
UGT2B7 promoter polymorphism A-842 G, which causes an increase 
in promoter activity, therefore resulting in higher levels of the enzyme. 
With more of the UGT2B7 enzyme present, the patient experienced an 
increased rate of morphine metabolism, which contributed to her poor 
analgesic response. Lastly, the patient also had a SNP in the gene for 
P-gp, which is involved in the distribution of morphine. The patient was 
heterozygous for the polymorphism C3435 T, which increases the stabil-
ity of the mRNA transcript and results in an expression of higher levels 
of the transporter. Consequently, the patient was less able to absorb and 
distribute morphine to various regions of the body, including the central 
nervous system. The overall end result of the patient having all three of 
these genetic polymorphisms was that she could not get adequate pain 
relief from morphine. 
Codeine: A Case Report 
Codeine does not produce an adequate analgesic response in 6-7 
percent of the Caucasian population because these individuals lack 
functional CYP2D6 enzymes. 2 This percentage of the population is 
homozygous for non-functional mutant CYP2D6 alleles and, therefore, 
is unable to convert codeine to morphine, which provides the pain relief. 
In another published case report, a 65-year-old woman was given what 
was considered to be standard doses of paracetamol, also known as 
acetaminophen, and codeine for the treatment of pain. However, only 
minor pain relief was seen, and subsequent increases in the doses were 
not found to improve the analgesia and resulted in the patient experienc-
ing undesirable side effects. The patient underwent genetic testing for 
CYP2D6 polymorphisms, and it was found that she completely lacked 
any functional CYP2D6 enzymes. Consequently, this patient was unable 
to get pain relief from codeine because she is part of the small percent-
age of the Caucasian population with this genetic variation in which 
morphine was not formed. 
Conclusion 
These case reports illustrate that there is a need to consider genetic 
factors when prescribing an opioid for analgesia because of the number 
of genetic polymorphisms in various enzymes, receptors and transport-
ers that can significantly alter the response to this class of medications.6 
For instance, being able to use genetic tests to identify a patient as 
a poor responder to morphine would allow an alternative opioid to be 
chosen as the first-line treatment, thereby minimizing the incidence and 
extent of pain experienced by the patient for the duration of therapy. 
If point-of-care genetic testing could be done to identify patients who 
lack functional CYP2D6 enzymes, these patients could be prescribed 
an alternative drug instead of codeine, which would ultimately spare 
the patient from experiencing inadequate pain relief as a result of their 
inability to convert codeine to morphine. In the future, the use of genetic 
screenings prior to prescribing and dispensing opioids may allow health 
care providers to prevent this type of insufficient drug therapy; however, 
further advancements are needed in this area in order for it to have a 
more significant role in clinical practice. As pharmacists, we can improve 
patient care by providing different analgesic options to patients whose 
pain is not adequately controlled by opioids. These opioid resistant pa-
tients could be affected by one or more genetic factors, including having 
a polymorphism in either a CYP450 or UGT enzyme. Pharmacists can 
be the health care provider to counsel patients on this issue and provide 
them with other options, such as finding another pain medication that 
is metabolized by different CYP450 enzymes or by proposing another 
route of delivery for their current medication. For example, using a 
transdermal or buccal delivery route for a medication will avoid extensive 
first-pass metabolism by the liver, allowing more drug to be available 
for the patient. This simple change can make a substantial difference 
in a patient's therapy by helping to alleviate more of the patient's pain. 
Although this area of pharmacotherapy is still in the beginning stages 
of development, pharmacists have the opportunity to use pharmacoge-
nomic methods to help improve patient care and enhance the outcome 
of a patient's opioid drug therapy. 
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Table 1. Phenotypic Designations for CYP2D6 Expression5 
Genotype Phenotypic Designation 
Two nonfunctional alleles Poor metabolizer (PM) 
At least one reduced function allele Intermediate metabolizer (IM) 
At least one functional allele Extensive metabolizer (EM) 
Multiple copies of a functional allele Ultrarapid metabolizer (UM) 
and/or an allele with a mutation in the 
promoter region 
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